Latest News

Testicular cancer mortality rates dip for Hispanic men


 

FROM ASCO GU 2022

A study of testicular cancer mortality finds worse outcomes among Hispanic men, but better outcomes among Black men.

The findings were reported at the American Society of Clinical Oncology Genitourinary Cancers Symposium.

Incidence rates for testicular cancer in the United States have increased slowly in recent decades, said Anushka Ghosh, a clinical research coordinatory with Massachusetts General Hospital, Boston. Her analysis found mortality increases from 1999 to 2019 to be significantly greater among Hispanic men. The increase was 0.0019 per 100,000, compared with a 0.0003 per 100,000 decrease among non-Hispanic men (comparison P = .010).

Among Black men, testicular cancer–specific mortality rates declined by 0.0007 per 100,000, compared with a marginally significant increase of 0.0006 per 100,000 among White men (P =.049).

“Given that testicular cancer generally has a favorable prognosis, it is concerning that the mortality rate for this disease is increasing,” said Sophia C. Kamran, MD, the study’s lead author and a radiation oncologist at Massachusetts General Hospital.

Dr. Kamran urged new efforts to understand these trends and to make testicular cancer care more accessible for all patients.

Ms. Ghosh said that other researchers have identified the same disparity among Hispanic men with prostate cancer. “Even though testicular cancer is a rare, our finding warrants further investigation to find the basis of these disparities to better serve the Hispanic community.”

Other studies have shown higher likelihood of later stage diagnosis and worse survival outcomes among Black patients.

No funding sources were reported for this study.

Recommended Reading

LGBTQ health care: There is reason to be hopeful
MDedge Internal Medicine
Cancer risk tied to some manufactured foods
MDedge Internal Medicine
For equality in prostate cancer outcomes, seek equality in treatment
MDedge Internal Medicine
Experts disappointed by NICE’s decision to reject prostate cancer drug
MDedge Internal Medicine
AI holds its own against pathologists for prostate cancer diagnosis
MDedge Internal Medicine
MRI far safer than CT for guiding radiotherapy in prostate cancer
MDedge Internal Medicine
63% of patients with upper tract urothelial carcinoma respond to chemo before surgery
MDedge Internal Medicine
Testicular cancer deaths rising among Hispanic men
MDedge Internal Medicine
Bladder cancer need not always require radical cystectomy
MDedge Internal Medicine
Sotorasib demonstrates clinically meaningful difference in pancreatic cancer
MDedge Internal Medicine